Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients by Robert M. Conry et al.
Conry et al. Clin Sarcoma Res  (2016) 6:6 
DOI 10.1186/s13569-016-0046-2
RESEARCH
Zoledronic acid in metastatic 
osteosarcoma: encouraging progression free 
survival in four consecutive patients
Robert M. Conry1*, Michael G. Rodriguez2 and Joseph G. Pressey3,4
Abstract 
Background: Zoledronic acid (ZA) is a third-generation bisphosphonate in widespread clinical use to reduce pain 
and skeletal events in patients from a variety of malignancies with bone metastases. Pre-clinical studies indicate that 
ZA inhibits osteosarcoma through direct anti-proliferative effects, immune activation and anti-angiogenic activity.
Methods: The purpose of this study was to evaluate the antitumor efficacy of ZA at standard dose until progres-
sion in patients with stage IV osteosarcoma lacking a standard of care treatment option proven to influence survival. 
Researchers retrospectively reviewed medical records of all patients at our institution with high-grade osteosarcoma 
presumed to be incurable due to metastases progressive after primary combination chemotherapy who received 
single agent ZA in an effort to delay progression.
Results: In our four-patient cohort following initiation of ZA, the median progression-free survival was 19 months, 
and median overall survival was 56+ months. Two of four patients have remained progression-free since starting ZA. 
The other two initially progressed after 18–20 months on ZA followed by metastasectomy of lung or dural metasta-
ses and further stability for over a year following resumption of ZA. After a 20-month progression-free interval on ZA 
alone, one patient had partial response following addition of pazopanib to ZA that likely contributed to long term dis-
ease control. The four patients experienced no significant toxicities despite protracted dosing of ZA for up to 5 years, 
and none have required chemotherapy since beginning ZA.
Conclusions: Single agent ZA was associated with encouraging progression-free survival in four consecutive 
patients with metastatic osteosarcoma. Prospective trials of single agent ZA are warranted as protracted maintenance 
therapy in surgically incurable osteosarcoma relapsed or refractory to first line combination chemotherapy with radio-
graphically measurable metastases.
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Background
Osteosarcoma is the most common malignant bone 
tumor in children and young adults. Despite aggres-
sive surgical and medical therapy, the estimated 5-year 
event-free survivals of patients presenting with local-
ized or metastatic disease are 50–70  % and less than 
20  %, respectively [1]. Patients with either unresectable 
primary tumors or distant metastases progressing after 
conventional primary chemotherapy have dismal out-
comes, little changed over the past 30 years [2]. There is 
no “standard” second-line systemic therapy for inoper-
able osteosarcoma progressing after conventional chem-
otherapy. Results of three cooperative group experiences 
in this population reveal median survival of 6 months [3], 
median time to progression of 2  months with only 6  % 
event-free survival at 6  months [4], and a 2-year post-
relapse survival <2 % [5]. Thus, novel systemic treatment 
approaches are urgently needed.
Zoledronic acid (ZA) is a third-generation, nitro-
gen-containing bisphosphonate analog of endogenous 
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pyrophosphate that strongly binds to calcium-containing 
hydroxyapatite bone mineral. Although the plasma half-
life of ZA is less than 24  h, bisphosphonates are stable 
in bone with a skeletal half-life of more than 300  days 
[6]. Osteosarcoma is characterized by the production 
of osteoid or immature bone containing focal calcium 
deposits of hydroxyapatite crystals [7]. Thus, ZA may 
preferentially concentrate in primary osteosarcomas as 
well as their lung and bone metastases and persist for 
years. ZA inhibits farnesyl diphosphate synthase, a key 
enzyme in the mevalonate pathway, and thus reduces 
protein prenylation essential for normal cell function and 
survival [8, 9]. Bone-resorbing osteoclasts internalize 
relatively large quantities of ZA and are thus particularly 
vulnerable to functional inhibition, underlying the wide-
spread use of this drug to reduce pain and skeletal-related 
events in adults with bone metastases [10]. However, 
nitrogen-containing bisphosphonates appear to have 
direct anti-proliferative and pro-apoptotic effects against 
normal osteoblasts and a variety of tumor cells, includ-
ing breast, myeloma, pancreatic and prostate cancers 
[11–15]. ZA has been shown to reduce primary tumor 
growth, decrease lung metastases and prolong survival 
in animal models of osteosarcoma [16–18]. ZA also acts 
synergistically with mTOR inhibition to decrease pro-
liferation of murine and human osteosarcoma cell lines 
in vitro and to reduce osteosarcoma tumor growth in two 
distinct syngeneic murine modals [19]. Ewing’s sarcoma 
is the second most frequent malignant bone tumor in 
adolescents and young adults. ZA inhibits Ewing’s sar-
coma cell invasion through down regulation of matrix 
metalloproteinase and significantly reduces development 
of spontaneous lung metastases in a nude mouse model 
of human Ewing’s sarcoma cells injected into the tibia 
[20].
The Children’s Oncology Group (COG) performed 
a phase I feasibility trial of monthly ZA for eight cycles 
with concurrent conventional multi-agent chemotherapy 
in 24 children with previously untreated, high-grade met-
astatic osteosarcoma [21]. The maximum tolerated dose 
(MTD) was equivalent to the standard adult dose for 
bone metastases, and there was a trend toward improved 
event-free survival at 2 years compared to historical data 
from intergroup study INT 0133 (p = 0.079). This manu-
script is the first reported clinical experience with ZA as 
single agent therapy for osteosarcoma.
Methods
With approval from The University of Alabama at Bir-
mingham institutional review board, the researchers 
retrospectively reviewed medical records of all patients 
at our institution with high-grade osteosarcoma treated 
from December 2010 to January 2015. This timeframe 
was selected for analysis to allow a minimum of 8 months 
of follow-up for progression-free survival prior to this 
report. Twenty-seven such patients were identified; four 
of whom were presumed to be incurable due to meta-
static osteosarcoma progressive after primary combina-
tion chemotherapy and received off-label ZA in an effort 
to delay progression. Those four consecutive patients so 
treated are the basis of this report. To provide details of 
each clinical situation and response to ZA, individual 
patient histories are briefly described in case report for-
mat. Treatment outcomes for the four patient cohort are 
summarized in Table 1.
Results
All four patients presented with high-grade osteosar-
coma without detectable metastases. All received neoad-
juvant and/or adjuvant chemotherapy with conventional 
doses of doxorubicin and cisplatin with or without 
high-dose methotrexate and ifosfamide. All underwent 
definitive surgical resection of the primary tumor using 
a limb-sparing approach in the three extremity cases. 
Patients 2 and 4 had microscopically positive soft tissue 
margins treated with post-operative external beam radi-
otherapy. All patients subsequently developed stage IV 
osteosarcoma involving the lungs that was treated with 
ZA. Patients 1 and 2 received ZA as consolidative treat-
ment following metastasectomies and a likely transient 
Table 1 Treatment outcomes with zoledronic acid
PFS progression-free survival; OS overall survival; NED no evidence of disease; SD stable disease
a sites of osteosarcoma active during or immediately preceding ZA
b calculated from start of ZA
Patient Sites of diseasea PFSb (months) Additional therapy Status at last visit OSb (months)
1 Lung 20 Pazopanib/surgery NED 63+
2 Lung 54+ None NED 54+
3 Lung and hilum 18 Radiation to hilum/neurosurgery SD 59+
4 Lung 14+ None SD 14+
Median 19 Median 56+
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response to salvage chemotherapy in the case of patient 
2. Patients 3 and 4 received ZA for treatment of persis-
tently measurable metastases to the lung and other sites. 
The University of Alabama at Birmingham Department 
of Anatomical Pathology histologically confirmed the 
diagnosis of high-grade osteosarcoma from the primary 
site of all four patients as well as from resection speci-
mens from lung metastases in patient 1 before and after 
ZA and patient 2 before ZA. Histological confirmation 
of metastatic high-grade osteosarcoma was also obtained 
at our academic center from bronchoscopic biopsy of a 
hilar lymph node and subsequent resection of a brain 
metastasis in patient 3.
Case #1
A 20-year-old male presented with osteosarcoma of the 
left tibia, and 16  months after completion of primary 
therapy a solitary metastasis of high-grade osteosar-
coma was wedge resected from the right upper lobe. 
Over the subsequent 5  years prior to treatment with 
ZA, he required bilateral pulmonary metastasectomies 
on four occasions with no objective response to multi-
ple intervening combination chemotherapy regimens 
including cyclophosphamide with topotecan, ifosfamide 
with etoposide, gemcitabine with docetaxel and cisplatin 
with vinorelbine. During that 5-year period, the longest 
progression-free interval was 6 months and the interval 
between metastasectomies progressively shortened from 
20 months to 17 to 11 and ultimately to 9 months. A new 
subpleural 6 mm left upper lobe metastasis was seen on 
chest CT performed in June 2010 (Fig. 1a) and markedly 
enlarged on chest CT in December 2010 (Fig. 1b) prior to 
his fifth metastasectomy. In an attempt to delay further 
recurrence, ZA was initiated at 4 mg every 6 weeks rather 
than a 4-week interval indicated for bone metastases 
due to lengthy travel to clinic. Chest computed tomog-
raphies (CTs) were performed at 3-month intervals. 
After a 20-month progression-free interval, a solitary 
8 mm metastasis to the left lung was detected (Fig. 1c). 
The patient continued ZA with the addition of oral pazo-
panib at 600 mg daily. The solitary metastasis responded 
to the combination of pazopanib and ZA, decreasing to 
3  mm following 2  months of therapy. After 7  months, 
pazopanib was reduced to 400 mg daily due to plateaued 
response (Fig. 1d) as well as mild to moderate anorexia, 
insomnia and hypertension. After 14  months of com-
bined pazopanib and ZA, chest computed tomography 
(CT) showed a stable  3  mm solitary left lung nodule, 
and ZA was discontinued to facilitate dental procedures 
related to advanced caries predating ZA use with no evi-
dence of osteonecrosis. Pazopanib was also discontinued 
4  months later to facilitate dental work with the lung 
nodule remaining stable after 18  months of pazopanib 
therapy. Chest CT after 3  months off therapy revealed 
enlargement of the left lung nodule from 3 to 17 mm, and 
positron emission tomography (PET) showed no disease 
elsewhere. The solitary left lung metastasis was wedge 
resected, and single agent ZA was resumed at the prior 
dose. The patient remains progression-free 20  months 
after surgery with overall survival 63+ months from the 
start of ZA.
Case #2
A 63-year-old male underwent left radical parotidectomy 
and neck dissection to resect an extraosseous osteosar-
coma with no lymph node involvement. Two years after 
completion of primary therapy a CT scan of the chest 
revealed a new right lung metastasis which was wedge 
resected. Repeat chest CT scan 3  months later dem-
onstrated five new pulmonary metastases. He was con-
sidered incurable due to rapid progression of multiple, 
bilateral pulmonary metastases 2 years after completion 
of optimal adjuvant chemotherapy for a man of his age. 
He received salvage chemotherapy with four cycles of 
Fig. 1 a Axial CT scan performed on 6/10/10 shows a new sub-
pleural 6 mm left upper lobe nodule. b Follow-up CT performed on 
12/10/10 shows interval increase in size of the pleural based left upper 
lobe nodule representing metastatic osteosarcoma at resection. c 
Axial CT performed on 3/28/11 shows a new 8 mm nodule in the left 
lower lobe. d Follow-up axial CT performed on 11/7/12 showed inter-
val decrease in size of the left lower lobe nodule to 3 mm, confirmed 
to be osteosarcoma at subsequent resection
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doxorubicin and dacarbazine since he was unable to tol-
erate additional cisplatin due to peripheral neuropathy. 
Chest CT scan showed a complete radiographic response 
which was followed by three cycles of vinorelbine with 
oral cyclophosphamide. Since the prognosis was dis-
mal, the patient began ZA at 4 mg every 6 weeks due to 
lengthy travel to clinic as consolidative therapy. He con-
tinued this schedule for 18  months followed by dosing 
every 3 months for 36 additional months without appar-
ent toxicity or relapse of osteosarcoma as determined by 
chest CT scans at 3-month intervals. He has been on ZA 
for 54+ months.
Case #3
A 48-year-old female presented with osteosarcoma 
of the right femur, and 38 months after completion of 
primary therapy a chest CT scan revealed an enlarg-
ing 11  mm right lung nodule, new calcified left hilar 
adenopathy and narrowing of the lingular bronchus. 
Bronchoscopic biopsy confirmed metastatic osteo-
sarcoma. Over the subsequent 19  months, she had no 
objective response to multiple chemotherapy regimens 
including ifosfamide with etoposide, cyclophospha-
mide with vinorelbine, gemcitabine, cisplatin and rida-
forolimus. Bilateral pulmonary metastases increased in 
size and number, and left hilar adenopathy increased 
from 1.9 to 4.1  cm with distal atelectasis, cough and 
dyspnea on exertion (Fig.  2a, b). Since standard treat-
ment options had been exhausted, ZA was initiated at 
3.5  mg every 4  weeks due to an abnormal glomerular 
filtration rate at baseline. After 18 months of ZA, bilat-
eral lung metastases remained stable, and the left hilar 
adenopathy increased modestly to 5  cm with progres-
sive atelectasis. Although she was stable by RECIST 
1.1 criteria, palliative radiation to 40 Gy in 8 fractions 
was delivered to the hilar mass to reduce dyspnea, and 
ZA was continued. After 26 additional months of ZA, 
the hilar adenopathy and multiple, bilateral pulmonary 
metastases remained stable by RECIST 1.1 criteria. A 
5 cm intracranial dural-based calcified falcine mass was 
incidentally detected on sinus films, and neurosurgical 
resection revealed metastatic osteosarcoma. She has 
remained on monthly ZA for 59+ months and is sta-
ble 16 months after resection of the intracranial metas-
tasis (Fig. 2c, d).
Case #4
A 65-year-old male presented with chondroblastic oste-
osarcoma of the left femur and multiple new bilateral 
lung metastases measuring up to 1  cm diameter devel-
oped during the fourth cycle of adjuvant chemother-
apy. These were confirmed to be progressive by two CT 
scans of the chest performed 6 weeks apart (Fig. 3a, b). 
Chemotherapy was discontinued, and ZA was initiated at 
4  mg every 4  weeks. After 14  months of follow-up, the 
patient remains stable with no local recurrence, pulmo-
nary metastases stable by RECIST 1.1 criteria (Fig.  3c) 
and no new lesions as determined by MRI and chest CT, 
respectively at 3 month intervals.
Fig. 2 a Coronal CT image on 3/31/11 showing a calcified left hilar 
mass with metastatic osteosarcoma biopsy confirmed. b Axial CT 
image performed on 3/31/11 showing a calcified nodule in the right 
lower lobe consistent with metastatic disease. c Coronal CT image 
performed on 12/11/15 shows grossly stable appearance of the calci-
fied left hilar mass. d Axial CT image performed on 12/11/15 shows a 
grossly stable appearance of the right lower lobe nodule
Fig. 3 Axial CT images performed on 12/11/14 (a) and 1/23/15 (b) 
show interval growth of a left lower lobe nodule from 3 to 6 mm. 
Follow-up axial CT image performed on 2/1/16 (c) shows a grossly 
stable 6 mm left lower lobe nodule
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Summary of outcomes
All patients had stage IV osteosarcoma and lacked a 
standard of care treatment option proven to significantly 
influence survival. The treatment outcomes with ZA are 
summarized in Table  1. Following initiation of ZA, the 
median progression free survival was 19  months, and 
median overall survival was 56+ months. At the time of 
this report, two of the four patients have no evidence of 
disease, and the other two have stable disease. None of 
the four patients have required chemotherapy since start-
ing ZA. The case of patient 1 is particularly compelling 
since ZA dramatically extended the progression-free 
interval following his fifth pulmonary metastasectomy 
to 20  months. Once another metastasis became detect-
able, it objectively responded to the addition of pazo-
panib to ZA for 14 months followed by resection, and he 
remains progression-free 20 months later on single agent 
ZA. Patient 3 demonstrated stable hilar and pulmonary 
metastases for a remarkable 44 months on ZA allowing 
her to survive long enough to develop a very uncommon 
metastasis to the dura possibly representing a sanctuary 
site of relatively poor drug penetration. Following resec-
tion of the intracranial metastasis, she has remained sta-
ble for an additional 16 months on ZA.
Discussion
Bisphosphonates are relatively well tolerated with side 
effects including electrolyte disturbances, flu-like symp-
toms, nausea and less commonly osteonecrosis of the 
jaw and renal dysfunction [22, 23]. The four patients 
reported herein receiving ZA for advanced osteosarcoma 
experienced no significant toxicities despite protracted 
dosing for up to 5  years. ZA is a convenient treatment 
for patients with incurable osteosarcoma with far less 
detrimental impact on quality of life than conventional 
chemotherapy.
Pre-clinical studies indicate that ZA inhibits osteosar-
coma through direct anti-proliferative effects, immune 
activation and anti-angiogenic activity. ZA directly inhib-
its human osteosarcoma cell proliferation and induces 
apoptosis in  vitro [24–26]. γδ T cells recognize small 
phosphoantigens associated with metabolites of bacte-
rial isoprenoid biosynthesis or the mevalonate pathway 
in eukaryotes [27]. ZA sensitizes tumor cells to γδ T cell 
cytotoxicity through accumulation of mevalonate path-
way intermediates within bisphosphonate-treated cells 
[28]. ZA promotes γδ T cell proliferation from peripheral 
blood mononuclear cells of osteosarcoma patients and 
enhances γδ T cell cytotoxicity against human osteosar-
coma cells [29, 30]. Vascular endothelial growth factor-A 
(VEGF-A) and vascular endothelial growth factor recep-
tor-1 (VEGFR-1) are highly expressed by aggressive oste-
osarcoma cells, but not in clonally-related less aggressive 
cell lines [31]. Plasma levels of VEGF-A are elevated in 
osteosarcoma patients, and ZA decreases circulating 
levels of VEGF-A in these patients [32, 33]. ZA inhib-
its tumor-associated angiogenesis not only via direct 
inhibition of endothelial cells, but also by decreasing 
VEGF-A expression in osteosarcoma. Furthermore, evi-
dence indicates that ZA induces apoptosis in aggressive 
osteosarcoma cells at least partly by inhibiting autocrine 
stimulation via VEGF-A and VEGFR signaling [31]. Thus, 
nitrogen-containing bisphosphonates have pleiotropic 
inhibitory effects on osteosarcoma and tumor-associated 
endothelial cells.
Inherent limitations in this study include the retrospec-
tive nature of the review and the small cohort of patients 
analyzed. However, this report does include all patients 
receiving single agent ZA to delay osteosarcoma progres-
sion at our institution during the specified timeframe.
COG has demonstrated the feasibility of co-adminis-
tering ZA with conventional chemotherapy for first line 
treatment of metastatic osteosarcoma, but the small trial 
was underpowered to detect efficacy of ZA, particu-
larly in the presence of highly active chemotherapy. A 
large, randomized French trial of conventional adjuvant 
chemotherapy with or without ZA for resectable primary 
osteosarcoma was stopped early due to futility with haz-
ard ratios for event-free survival and death exceeding 
unity in the ZA cohort. Although not statistically sig-
nificant, these data suggests that ZA in this context may 
increase mortality [34]. However, this trial may likewise 
have been suboptimally designed to evaluate efficacy of 
ZA in this disease. Direct antiproliferative effects of ZA 
could actually protect osteosarcoma cells from tumori-
cidal effects of chemotherapy. Enhancement of antitu-
mor immune responses by ZA could be undermined by 
concurrent cytotoxic chemotherapy, and antiangiogenic 
actions of ZA may have little relevance in treating micro-
metastases in the adjuvant setting. ZA may actually have 
greater efficacy against surgically incurable macroscopic 
osteosarcoma used as a single agent or in combina-
tion with the mTOR inhibitor everolimus or the VEGFR 
tyrosine kinase inhibitor pazopanib, targeting tumor cell 
proliferation and angiogenesis, respectively [19, 35]. The 
combination of ZA and sirolimus has recently been dem-
onstrated to be effective and tolerable therapy for a young 
adult with aggressive lymphatic malformations associ-
ated with Gorham-Stout disease [36]. Intriguing results 
from a recent study of the multi-tyrosine kinase inhibi-
tor sorafenib with activity against VEGFR in combination 
with everolimus further support the use of such agents 
in recurrent or refractory osteosarcoma [37]. In fact, this 
trial represents the first positive study in at least 25 years 
in patients with relapsed osteosarcoma [38]. Interest-
ingly, patient 1 in this report experienced disease control 
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for 20 months on single agent ZA followed by emergence 
of another lung metastasis that objectively responded for 
over 14 months to the addition of pazopanib to ZA. We 
have also observed objective response of multiple pulmo-
nary metastases to combined ZA and pazopanib for over 
9  months in a patient with relapsed osteosarcoma not 
included here due to lack of single agent ZA use.
Conclusions
Zoledronic acid represents a convenient, well tolerated 
therapy which may provide durable control of incur-
able osteosarcoma. Therefore, prospective trials of single 
agent ZA are warranted in surgically incurable osteo-
sarcoma relapsed or refractory to first line conventional 
combination chemotherapy with radiographically meas-
urable metastases.
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